Ozempic Beauty Standards and What the Industry Is Doing With Them
Thinness has always been sold. For most of the last century, the vehicle was advertising— billboards, fashion campaigns, magazine covers, the consistent visual message that a slim body is a better body. What has changed is the delivery mechanism. It is now, increasingly, a prescription to achieve the Ozempic beauty standard.
Around 12% of US adults have used GLP-1 medications like Ozempic, according to a 2024 report from Northwestern. The drugs were developed to treat type 2 diabetes and obesity, and for many people they do exactly that. But the cultural conversation around them has moved well beyond medical need. Weight loss influencers, celebrity speculation, and campaigns like Ro's 2023 "a weekly shot to lose weight" have repositioned Ozempic as something closer to a beauty routine than a medical treatment. The distinction matters, because when a drug becomes a beauty standard, the logic that drove decades of harmful diet culture does not disappear— it gets a prescription pad.
What Ozempic Beauty Standards Are Actually Doing
The mechanism behind GLP-1 drugs — stimulating insulin and slowing the rate at which the stomach empties, increasing the sense of fullness — means users can eat significantly less without feeling hungry. For people in eating disorder recovery, or with a history of restrictive eating, that is not a neutral effect. The National Alliance for Eating Disorders has noted that appetite suppression can make recovery from restrictive eating more complex, disrupting the relationship between hunger and fullness that recovery depends on. The Guardian reported in 2025 that clinicians are increasingly having to navigate this tension.
There is also what happens after the weight loss. Psychology Today noted in 2026 that for some users, feeling physically different can sharpen their awareness of how they were treated before — reinforcing the belief that body size determines social worth. The drug does not create that belief. It did not need to. The industry built it over decades. Ozempic just makes the stakes feel more immediate.
Then there is what the industry has already started calling "Ozempic Face" — the gaunt, sagging facial appearance that can result from rapid weight loss — and its counterpart, "Ozempic Body." The pattern is familiar: the fix reveals a new problem, the new problem requires a new product, and the cycle of chasing a moving standard continues. In this case the product is cosmetic procedures, and the people selling them are well aware of the opportunity.
Ozempic is not a beauty product. But it is being used as one, and the beauty industry is paying close attention. If the norm shifts from "looking healthy" to "thin enough," and that shift is backed by a multi-billion dollar pharmaceutical market, the last decade of progress on body diversity and representation becomes considerably harder to sustain. The National Eating Disorders Association warned in 2024 that widespread Ozempic use risks intensifying thin idealisation, weight stigma, and fatphobia. Body shame tends to follow when large bodies are framed as the medical problem and thin bodies as the solution. The drug itself is not the issue. The culture it is being absorbed into is.
Index:MH sets measurable standards for how the beauty and fashion industry affects consumer mental health. To find out more about our work, visit indexmh.org.
